Klinické štúdie

účinok baktérie Streptococcus Salivarius je overený mnohými štúdiami

Okrem niekoľkých menších štúdií s nádejnými výsledkami, bolo urobených niekoľko väčších klinických štúdií overujúcich účinok probiotického kmeňa Streptococcus salivarius K12:

Di Pierro et al, 2013, Italy
Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013 Mar;13(3):339-43.

Di Pierro et al, 2012, Italy
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7

Ishijima et al, 2012, Japan and New Zealand
Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. Appl Environ Microbiol. 2012 Apr;78(7):2190-9.

Guglielmetti et al, 2010, Italy
Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl Environ Microbiol. 2010 Jun;76(12):3948-58.

Horz et al, 2007, Germany
Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007 Apr;22 (2):126-30.

Tagg et al, 2006, New Zealand
Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections. International Congress Series, 2006, Vol 128: 347-350

Wescombe et al, 2006, New Zealand
Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl. Environ. Microbiol. 2006 Feb 72(2):1459-1466.

Tagg et al, 2004, New Zealand
Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004 May;119 Suppl:13-6.

Dierksen et al, 2000, New Zealand
The influence of indigenous bacteriocin-producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. In: Streptococci and streptococcal diseases entering the new millennium. 2000 p81-85.

DENTAL HEALTH
Burton et al, 2013, New Zealand
Influence of the probiotic Streptococcus salivarius strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. J. Med. Microbiol. 2013 62:DOI 10.1099/jmm.0.056663-0

James & Tagg, 1991, New Zealand
The prevention of dental caries by BLIS-mediated inhibition of mutans streptococci. N Z Dent J. 1991 Jul;87(389):80-3.

UPPER RESPIRATORY TRACT INFECTIONS
Fiedler et al, 2013, Germany
Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection. Appl Environ Microbiol. 2013 Feb;79(4):1265-76.

Di Pierro et al, 2012, Italy
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7

Santagati et al, 2012, Italy
Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol Med Microbiol 2012 65:23-31

Power et al, 2008, New Zealand
Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008 Jun 17.

HALITOSIS
Masdea et al, 2012, Switzerland
Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour. Arch Oral Biol. 2012 Aug;57(8):1041-7.

Burton et al, 2006, New Zealand
A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters, J Appl Microbiol. 2006 Apr; 100(4):754-64.

Kazor et al, 2003, USA
Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol. 2003 Feb;41(2):558-563

SAFETY
Barretto et al, 2012, Switzerland
Genome sequence of the lantibiotic bacteriocin producer Streptococcus salivarius strain K12. J Bacteriol. 2012 Nov;194(21):5959-60.

Burton et al, 2011, New Zealand and USA
Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2011 Sep;49(9):2356-64.

Heng et al, 2011, New Zealand
Genome sequence of the bacteriocin-producing oral probiotic Streptococcus salivarius strain M18. J. Bact. 2011 Nov 193:6402-6403

Burton et al, 2010, New Zealand
Extended safety data for the oral cavity probiotic Streptococcus salivarius K12. Probiotics and Antimicro. Prot. 2010 2:135-144.

Burton et al, 2006, New Zealand
Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006 Apr;72(4):3050-3.

IMMUNITY
Groeger et al, 2011, Germany
B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. Immunobiology. 2011 Dec;216(12):1302-10.

Cosseau et al, 2008, Canada and United Kingdom
The commensal Streptococcus salivarius K12 down-regulates the innate immune responses of human epithelial cells and promotes hostmicrobe homeostasis. Infection and Immunity, Sept. 2008, p. 4163–4175.

OTITIS MEDIA
Di Pierro et al, 2012, Italy
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7.

Tagg et al, 2003, New Zealand
Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol. 2003 Sep;52(Pt 9):829-33.

Wescombe et al, 2006, New Zealand & Canada
Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius, Antonie Van Leeuwenhoek. 2006 Oct;90 (3):269-80

Hyink et al., 2007, New Zealand
Salivaricin A2 and the novel antibiotic salivaricin B, are encoded by adjacent loci on a 190 kb transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 73(4): 1107-13.

Wescombe et al, 2006, New Zealand
Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol. 2006 Feb;72(2):1459-66.

REVIEWS
Wescombe et al, 2012, New Zealand
Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 2012 7(12):1355-1371.

Hale et al, 2012, New Zealand
BLIS-producing probiotics targeting the oral cavity. Microbiology Australia. 2012 Sept 33(3):103-105.

Burton et al, 2011, New Zealand and Canada
Beneficial microbes for the oral cavity: time to harness the oral streptococci? Beneficial microbes. 2011 June 2(2):93-101

Wescombe et al, 2010, New Zealand
Something old and something new: An update on the amazing repertoire of bacteriocins produced by Streptococcus salivarius. Probiotics & Antimicro. Prot. 2010 2:37-45

Tagg, 2009, New Zealand
Streptococcal bacteriocin-like inhibitory substances: some personal insights into the bacteriocin-like activities produced by streptococci good and bad. Probiotics and Antimicro. Prot. 2009 1:60-66.

Wescombe et al, 2009, New Zealand
Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbial. 2009 4(7):819-35

Tagg et al, 2008, New Zealand
Streptococci as effector organisms for probiotic and replacement therapy. In: Therapeutic Microbiology: Probiotic and Related Strategies. J. Versalovic and M. Wilson, American Society for Microbiology. p61-81.

Tagg, 2007, New Zealand
Application of bacterial pathogens in replacement therapy. In: Patho-Biotechnology. R. Sleator and C. Hill Landes Bioscience.

Heng et al, 2007, New Zealand
The diversity of bacteriocins in gram-positive bacteria. In: Ecology and Evolution. M. Riley and M. Chavan. p45-92.

Tagg et al, 2003, New Zealand
Bacterial replacement therapy: adapting 'germ warfare' to infection prevention, Trends Biotechnol. 2003 May;21 (5):217-23.

Kontakt

Julamedic s.r.o
Allendeho 2769/38 Poprad 059 51 Slovensko
IČO: 48 127 205, zapísaná v Obchodnom registri Okresného súdu Prešov, vložka číslo: 31447/P
E-mail: info@bactoral.sk